Monopteros: Medicxi-backed start-up believes MALT1 inhibition can prime tumors for checkpoint blockade
Emerging Company Profile: Monopteros’ $20M round to support Phase I/Ib trial, first in solid tumors
Monopteros has won the backing of Medicxi in a $20 million series A round designed to see whether its MALT1 inhibitor can selectively reprogram Tregs to enhance checkpoint inhibitors’ efficacy.
Monopteros Therapeutics Inc. has already dosed the first patient in a Phase I/Ib trial of MPT-0118, its oral MALT1 inhibitor. CEO Peter Keller told BioCentury the two-year-old company, which emerged from stealth Thursday, is the first company to test a MALT1 inhibitor in patients with solid tumors, and is aiming to be first in class in that area...
BCIQ Company Profiles
BCIQ Target Profiles
Mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1)